Triple immunotherapy cocktail shows promise against tough cancers

NCT ID NCT03744468

Completed Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now complete, and results will help guide future research on these combinations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tislelizumab, surzebiclimab, and alcestobart (three immunotherapy drugs that help the immune system attack cancer)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to all patients. Side effects from immunotherapy can be serious, including immune-related inflammation in healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HNSCC FOR PHASE 2 DOSE EXPANSION LOCALLY ADVANCED OR METASTATIC SOLID TUMORS FOR PHASE 1, DOSE ESCALATION AND PHASE 2 SAFETY LEAD-IN LOCALLY ADVANCED OR METASTATIC SOLID TUMORS FOR PHASE 1,DOSE ESCALATION AND PHASE 2 SAFETY LEAD-IN, HNSCC, NSCLC AND RCC PARTICIPANTS FOR PHASE 2 NSCLC FOR PHASE 2 DOSE EXPANSION

Contacts and locations

Locations

Ajou University Hospital

Suwon, 16499, South Korea
Asan Medical Center

SongpaGu, Seoul Teugbyeolsi, 05505, South Korea
Box Hill Hospital

Box Hill, Victoria, VIC 3128, Australia
Cabrini Research and Education Institute

Malvern, Victoria, VIC 3144, Australia
Calvary North Adelaide Hospital

North Adelaide, South Australia, SA 5006, Australia
Centre de Lutte Contre Le Cancer Francois Baclesse

Caen, 14000, France
Centre de Lutte Contre Le Cancer Institut Bergonie

Bordeaux, 33000, France
Chao Family Comprehensive Cancer Center

Orange, California, 92868-3201, United States
Chungbuk National University Hospital

SeowonGu CheongjuSi, Chungcheongbukdo, 28644, South Korea
Fondazione Irccs Istituto Nazionale Dei Tumori

Milan, 20133, Italy
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111-2434, United States
Gachon University Gil Medical Center

NamdongGu, Incheon Gwang'Yeogsi, 21565, South Korea
Gold Coast University Hospital

Southport, Queensland, QLD 4215, Australia
Hollywood Private Hospital

Nedlands, Western Australia, WA 6009, Australia
Hospital Clinico San Carlos

Madrid, 28040, Spain
Hospital Universitario Hm Madrid Sanchinarro

Madrid, 28050, Spain
Hospital Universitario Virgen Del Rocio

Seville, 41013, Spain
Institut Catala Doncologia

Barcelona, 08908, Spain
Institut Curie Paris

Paris, 75005, France
Irccs Azienda Ospedaliero Universitaria Bologna

Bologna, 40138, Italy
Istituto Di Candiolo Irccs

Torino, 10060, Italy
Linear Clinical Research

Nedlands, Western Australia, WA 6009, Australia
Lyell McEwin Hospital

Elizabeth Vale, South Australia, SA 5112, Australia
Peter Maccallum Cancer Centre

Melbourne, Victoria, VIC 3000, Australia
Schar Cancer Institute

Fairfax, Virginia, 22031-4867, United States
Severance Hospital Yonsei University Health System

SeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea
Sunshine Coast Hospital and Health Service

Birtinya, Queensland, QLD 4575, Australia
Sydney Southwest Private Hospital

Liverpool, New South Wales, NSW 2170, Australia
The Catholic University of Korea, Seoul St Marys Hospital

SeochoGu, Seoul Teugbyeolsi, 06591, South Korea
The Catholic University of Korea, St Vincents Hospital

PaldalGu SuwonSi, Gyeonggi-do, 16247, South Korea
The University of Texas Md Anderson Cancer Center

Houston, Texas, 77030-4009, United States
Ulsan University Hospital

Donggu, Ulsan Gwang'Yeogsi, 44033, South Korea
University of Chicago Medical Center

Chicago, Illinois, 60637-1443, United States
University of Colorado Cancer Center

Aurora, Colorado, 80045-2517, United States
University of Kentucky Markey Cancer Center

Lexington, Kentucky, 40536-7001, United States
University of North Carolina At Chapel Hill

Chapel Hill, North Carolina, 27514-4220, United States
University of Virginia

Charlottesville, Virginia, 22908-0817, United States
Ut Health San Antonio Mays Cancer Center

San Antonio, Texas, 78229-4427, United States
Weill Cornell Medical College Newyork Presbyterian Hospital

New York, New York, 10065-4870, United States
Western Health Sunshine Hospital

St Albans, Victoria, VIC 3021, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.